Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Size, Share & Trends Analysis Report, By Treatment (Medications, Surgery), By Drug Class (NSAIDs, Corticosteroids, csDMARDs, bDMARDs, tsDMARDs), By Route of Administration (Oral, Injectable), Forecast Period (2026–2035)

Published: May 2026 | Report Code: OMR2029481 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Rheumatoid arthritis market size was valued at $54 billion in 2025 and is projected to reach $90 billion by 2035, expanding at a CAGR of 5.2% during the forecast period (2026–2035). The market growth is primarily driven by the increasing prevalence of autoimmune disorders, advancements in biologic therapies, and rising healthcare expenditure globally.

According to the World Health Organization, rheumatoid arthritis affects more than 18 million individuals of the global population, making it one of the most common chronic inflammatory joint diseases. Additionally, data from the European Federation of Pharmaceutical Industries and Associations highlights growing investments in biologics and targeted therapies, accelerating innovation in disease management.

The demand for effective long-term treatment solutions is increasing due to aging populations and rising disability rates associated with rheumatoid arthritis. Major end-use sectors include hospitals, specialty clinics, and home healthcare settings. Furthermore, the adoption of precision medicine and targeted synthetic DMARDs is reshaping the treatment landscape, contributing significantly to market expansion.

Market Dynamics

Rising Prevalence of Autoimmune Diseases Driving Market Growth

The increasing incidence of autoimmune diseases globally is a major driver for the rheumatoid arthritis market. According to the World Health Organization, musculoskeletal conditions are among the leading causes of disability globally, with rheumatoid arthritis significantly contributing to years lived with disability. Aging populations, particularly in developed regions, further amplify disease prevalence and treatment demand.

Additionally, the IQVIA reports that global spending on specialty medicines, including biologics for autoimmune diseases, continues to rise, reflecting increasing adoption of advanced therapies. Pharmaceutical companies are focusing on innovative drug development, particularly biologic DMARDs and JAK inhibitors, to improve patient outcomes. Between 2025 and 2026, companies are investing heavily in clinical trials and expanding their biologics portfolios to capture market share. Furthermore, improved diagnostic techniques and early disease detection are enhancing treatment rates, thereby supporting sustained market growth globally.

High Treatment Costs and Safety Concerns Restraining Market Expansion

Despite strong growth prospects, the rheumatoid arthritis market faces challenges related to high treatment costs and potential side effects of advanced therapies. Biologic drugs and targeted synthetic DMARDs are often expensive, limiting accessibility in low- and middle-income countries. According to the Organisation for Economic Co-operation and Development, rising healthcare costs remain a major concern, with specialty drugs accounting for a growing share of pharmaceutical expenditure.

Additionally, stringent regulatory requirements imposed by agencies such as the U.S. Food and Drug Administration can delay drug approvals and increase development costs. Safety concerns, including risks of infections and long-term immunosuppression associated with biologics, further limit widespread adoption. Supply chain disruptions and biosimilar competition also create pricing pressures for manufacturers. However, companies are responding by investing in biosimilars, improving manufacturing efficiency, and expanding patient assistance programs to enhance affordability and market penetration.

Market Segmentation

  • Based on the treatment, the market is segmented into medications and surgery.
  • Based on the drug class, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs / JAK inhibitors).
  • Based on the route of administration, the market is segmented into oral and injectable.

Biologic DMARDs Segment Leads the Market

The biologic DMARDs (bDMARDs) segment dominates the rheumatoid arthritis market due to its superior efficacy in controlling disease progression and reducing joint damage. These therapies target specific components of the immune system, offering better outcomes compared to conventional treatments.

Pharmaceutical companies have significantly invested in biologics between 2022 and 2026, with multiple product launches and pipeline advancements. Increased physician preference for biologics, especially in moderate-to-severe cases, has driven their widespread adoption. Additionally, favorable reimbursement policies in developed regions have supported market growth. The growing availability of biosimilars is further expanding access to biologic therapies, making them more affordable and contributing to segment dominance globally.

Targeted Synthetic DMARDs Segment to Record Strong Growth

The targeted synthetic DMARDs (tsDMARDs), particularly JAK inhibitors, are expected to witness the fastest growth during the forecast period. These oral therapies provide convenience, rapid onset of action, and improved patient compliance compared to injectable biologics.

Technological advancements in drug discovery and precision medicine are driving innovation in this segment. Increasing investments in R&D and clinical trials are leading to the development of next-generation JAK inhibitors with improved safety profiles. Furthermore, rising demand for personalized treatment approaches and the shift toward oral administration are fueling the growth of tsDMARDs. Pharmaceutical companies are actively expanding their portfolios in this segment to capitalize on emerging opportunities.

Regional Outlook

The global rheumatoid arthritis market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the rheumatoid arthritis market due to high healthcare spending, advanced treatment infrastructure, and the strong presence of leading pharmaceutical companies. According to the Centers for Disease Control and Prevention, millions of adults in the U.S. are affected by arthritis, driving demand for effective therapies. Additionally, the Pharmaceutical Research and Manufacturers of America highlights substantial investments in biologics and innovative therapies, further strengthening market growth. Favourable reimbursement policies and rapid adoption of advanced drugs continue to position the U.S. as a key revenue contributor.

China to Record Strong Growth

China is expected to witness significant growth due to expanding healthcare infrastructure, rising disease awareness, and increasing pharmaceutical manufacturing capabilities. According to the World Health Organization, the burden of chronic diseases is increasing rapidly in the Asia-Pacific region, including autoimmune disorders. Countries like India are growing participation in global pharmaceutical trade, supported by data from the International Trade Centre, which reflects increasing production and export of pharmaceutical products. Government initiatives to improve healthcare access and encourage domestic drug manufacturing are further boosting market expansion in China.

Market Player Outlook

The rheumatoid arthritis market is highly competitive, characterized by strong R&D investments, product innovation, and strategic collaborations. Leading players such as AbbVie Inc., Johnson & Johnson (Janssen), Pfizer Inc., Amgen Inc., and Roche (Genentech) dominate the market through extensive biologics portfolios and global distribution networks.

These companies are focusing on developing next-generation therapies, including biosimilars and targeted treatments, to maintain a competitive advantage. Strategic partnerships, mergers, and acquisitions are also common, enabling companies to expand their product pipelines and geographical presence. Additionally, advancements in biotechnology and precision medicine are reshaping the competitive landscape.

Recent Developments

  • In October 2025, Hikma Pharmaceuticals and Celltrion Inc. expanded their strategic partnership through exclusive licensing agreements to improve access to biosimilars across the MENA region. The collaboration will introduce six cost-effective biosimilar therapies targeting key areas such as oncology, immune disorders, and ophthalmology, enhancing treatment availability for patients. Under the agreement, Hikma will lead commercialization while Celltrion will manage development and supply.
  • In January 2024, AbbVie is expanding its Singapore manufacturing facility with a $223 million investment to significantly boost its global biologics capacity, adding 24,000 liters of drug-substance manufacturing. This strategic move, breaking ground in early 2024 and becoming operational in 2026, strengthens the company's ability to produce innovative treatments for immunology and oncology.

 

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global rheumatoid arthritis market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

 

  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Rheumatoid Arthritis Market Sales Analysis – Treatment | Drug Class | Route of Administration ($ Million)
  • Rheumatoid Arthritis Market Size: Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

    2.2.1 Key Rheumatoid Arthritis Market Trends    

    2.2.2 Market Recommendations    

2.3 Porter's Five Forces Analysis for the Rheumatoid Arthritis Market

    2.3.1 Competitive Rivalry    

    2.3.2 Threat of New Entrants    

    2.3.3 Bargaining Power of Suppliers    

    2.3.4 Bargaining Power of Buyers    

    2.3.5 Threat of Substitutes    

  1. Market Determinants

3.1 Market Drivers

    3.1.1 Drivers for the Global Rheumatoid Arthritis Market: Impact Analysis    

3.2 Market Pain Points and Challenges

    3.2.1 Restraints For Global Rheumatoid Arthritis Market: Impact Analysis    

3.3 Market Opportunities

    3.3.1 Opportunities for the Global Rheumatoid Arthritis Market: Impact Analysis    

  1. Competitive Landscape

4.1 Competitive Dashboard – Rheumatoid Arthritis Market Size, Market Revenue, and Share by Manufacturers

  • Rheumatoid Arthritis Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 AbbVie Inc.

  4.2.1.1 Overview 

  4.2.1.2 Product Portfolio 

  4.2.1.3 Financial Analysis 

  4.2.1.4 SWOT Analysis 

  4.2.1.5 Business Strategy 

4.2.2 Johnson & Johnson (Janssen)

  4.2.2.1 Overview 

  4.2.2.2 Product Portfolio 

  4.2.2.3 Financial Analysis 

  4.2.2.4 SWOT Analysis 

  4.2.2.5 Business Strategy 

4.2.3 Pfizer Inc.

  4.2.3.1 Overview 

  4.2.3.2 Product Portfolio 

  4.2.3.3 Financial Analysis 

  4.2.3.4 SWOT Analysis 

  4.2.3.5 Business Strategy 

4.2.4 Amgen Inc.

  4.2.4.1 Overview 

  4.2.4.2 Product Portfolio 

  4.2.4.3 Financial Analysis 

  4.2.4.4 SWOT Analysis 

  4.2.4.5 Business Strategy 

4.2.5 Roche (Genentech)

  4.2.5.1 Overview 

  4.2.5.2 Product Portfolio 

  4.2.5.3 Financial Analysis 

  4.2.5.4 SWOT Analysis 

  4.2.5.5 Business Strategy 

4.3 Top Winning Strategies by Market Players

  4.3.1 Merger and Acquisition 

  4.3.2 Product Launch 

  4.3.3 Partnership And Collaboration 

  1. Global Rheumatoid Arthritis Market Sales Analysis by Treatment ($ Million)

5.1 Medications

5.2 Surgery

  1. Global Rheumatoid Arthritis Market Sales Analysis by Drug Class ($ Million)

6.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

6.2 Corticosteroids

6.3 Conventional Synthetic DMARDs (csDMARDs)

6.4 Biologic DMARDs (bDMARDs)

6.5 Targeted Synthetic DMARDs (tsDMARDs / JAK Inhibitors)

  1. Global Rheumatoid Arthritis Market Sales Analysis by Route of Administration ($ Million)

7.1 Oral

7.2 Injectable

  1. Regional Analysis

 8.1 North American Rheumatoid Arthritis Market Sales Analysis – Treatment | Drug Class | Route of Administration | Country ($ Million) 

            8.1.1 United States    

            8.1.2 Canada    

 8.2 European Rheumatoid Arthritis Market Sales Analysis – Treatment | Drug Class | Route of Administration | Country ($ Million) 

            8.2.1 UK    

            8.2.2 Germany    

            8.2.3 Italy    

            8.2.4 Spain    

            8.2.5 France    

            8.2.6 Russia    

            8.2.7 Rest of Europe   

 8.3 Asia-Pacific Rheumatoid Arthritis Market Sales Analysis – Treatment | Drug Class | Route of Administration | Country ($ Million) 

            8.3.1 China    

            8.3.2 Japan    

            8.3.3 South Korea    

            8.3.4 India    

            8.3.5 Australia & New Zealand    

            8.3.6 ASEAN Countries    

            8.3.7 Rest of Asia-Pacific    

 8.4 Rest of the World Rheumatoid Arthritis Market Sales Analysis – Treatment | Drug Class | Route of Administration | Country ($ Million) 

            8.4.1 Latin America    

            8.4.2 Middle East and Africa    

  1. Company Profiles

   9.1 AstraZeneca PLC 

          9.1.1 Quick Facts 

          9.1.2 Company Overview 

          9.1.3 Product Portfolio 

          9.1.4 Business Strategies 

   9.2 Biogen Inc. 

          9.2.1 Quick Facts 

          9.2.2 Company Overview 

          9.2.3 Product Portfolio 

          9.2.4 Business Strategies 

   9.3 Boehringer Ingelheim 

          9.3.1 Quick Facts 

          9.3.2 Company Overview 

          9.3.3 Product Portfolio 

          9.3.4 Business Strategies 

   9.4 Bristol Myers Squibb 

          9.4.1 Quick Facts 

          9.4.2 Company Overview 

          9.4.3 Product Portfolio 

          9.4.4 Business Strategies 

   9.5 Celltrion, Inc. 

          9.5.1 Quick Facts 

          9.5.2 Company Overview 

          9.5.3 Product Portfolio 

          9.5.4 Business Strategies 

   9.6 Chugai Pharmaceutical Co. 

          9.6.1 Quick Facts 

          9.6.2 Company Overview 

          9.6.3 Product Portfolio 

          9.6.4 Business Strategies 

   9.7 Eisai Co., Ltd. 

          9.7.1 Quick Facts 

          9.7.2 Company Overview 

          9.7.3 Product Portfolio 

          9.7.4 Business Strategies 

   9.8 Eli Lilly and Company 

          9.8.1 Quick Facts 

          9.8.2 Company Overview 

          9.8.3 Product Portfolio 

          9.8.4 Business Strategies 

   9.9 Gilead Sciences, Inc. 

          9.9.1 Quick Facts 

          9.9.2 Company Overview 

          9.9.3 Product Portfolio 

          9.9.4 Business Strategies 

   9.10 GlaxoSmithKline (GSK) 

          9.10.1 Quick Facts 

          9.10.2 Company Overview 

          9.10.3 Product Portfolio 

          9.10.4 Business Strategies 

   9.11 Hikma Pharmaceuticals 

          9.11.1 Quick Facts 

          9.11.2 Company Overview 

          9.11.3 Product Portfolio 

          9.11.4 Business Strategies 

   9.12 Merck & Co. (MSD) 

          9.12.1 Quick Facts 

          9.12.2 Company Overview 

          9.12.3 Product Portfolio 

          9.12.4 Business Strategies 

   9.13 Mitsubishi Tanabe Pharma 

          9.13.1 Quick Facts 

          9.13.2 Company Overview 

          9.13.3 Product Portfolio 

          9.13.4 Business Strategies 

   9.14 Novartis AG (Sandoz) 

          9.14.1 Quick Facts 

          9.14.2 Company Overview 

          9.14.3 Product Portfolio 

          9.14.4 Business Strategies 

   9.15 Organon & Co. 

          9.15.1 Quick Facts 

          9.15.2 Company Overview 

          9.15.3 Product Portfolio 

          9.15.4 Business Strategies 

   9.16 Samsung Bioepis 

          9.16.1 Quick Facts 

          9.16.2 Company Overview 

          9.16.3 Product Portfolio 

          9.16.4 Business Strategies 

   9.17 Sanofi (Regeneron) 

          9.17.1 Quick Facts 

          9.17.2 Company Overview 

          9.17.3 Product Portfolio 

          9.17.4 Business Strategies 

   9.18 Teva Pharmaceutical Industries 

          9.18.1 Quick Facts 

          9.18.2 Company Overview 

          9.18.3 Product Portfolio 

          9.18.4 Business Strategies 

   9.19 UCB S.A. 

          9.19.1 Quick Facts 

          9.19.2 Company Overview 

          9.19.3 Product Portfolio 

          9.19.4 Business Strategies 

   9.20 Viatris Inc. 

          9.20.1 Quick Facts 

          9.20.2 Company Overview 

          9.20.3 Product Portfolio 

          9.20.4 Business Strategies 

1. Global Rheumatoid Arthritis Market Research and Analysis by Treatment, 2025–2035 ($ Million)

2. Global Medications Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

3. Global Surgery Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

4. Global Rheumatoid Arthritis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

5. Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

6. Global Corticosteroids Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

7. Global Conventional Synthetic DMARDs Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

8. Global Biologic DMARDs Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

9. Global Targeted Synthetic DMARDs Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

10. Global Rheumatoid Arthritis Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

11. Global Oral Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

12. Global Injectable Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

13. Global Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

14. North America Rheumatoid Arthritis Market Research and Analysis by Country, 2025–2035 ($ Million)

15. North America Rheumatoid Arthritis Market Research and Analysis by Treatment, 2025–2035 ($ Million)

16. North America Rheumatoid Arthritis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

17. North America Rheumatoid Arthritis Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

18. Europe Rheumatoid Arthritis Market Research and Analysis by Country, 2025–2035 ($ Million)

19. Europe Rheumatoid Arthritis Market Research and Analysis by Treatment, 2025–2035 ($ Million)

20. Europe Rheumatoid Arthritis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

21. Europe Rheumatoid Arthritis Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

22. Asia-Pacific Rheumatoid Arthritis Market Research and Analysis by Country, 2025–2035 ($ Million)

23. Asia-Pacific Rheumatoid Arthritis Market Research and Analysis by Treatment, 2025–2035 ($ Million)

24. Asia-Pacific Rheumatoid Arthritis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

25. Asia-Pacific Rheumatoid Arthritis Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

26. Rest of the World Rheumatoid Arthritis Market Research and Analysis by Region, 2025–2035 ($ Million)

27. Rest of the World Rheumatoid Arthritis Market Research and Analysis by Treatment, 2025–2035 ($ Million)

28. Rest of the World Rheumatoid Arthritis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

29. Rest of the World Rheumatoid Arthritis Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

1. Global Rheumatoid Arthritis Market Size by Treatment, 2025 Vs 2035 (%)

2. Global Medications Rheumatoid Arthritis Market Research and Analysis by Region, 2025 vs 2035 (%)

3. Global Surgery Rheumatoid Arthritis Market Research and Analysis by Region, 2025 Vs 2035 (%)

4. Global Rheumatoid Arthritis Market Size by Drug Class, 2025 Vs 2035 (%)

5. Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Rheumatoid Arthritis Market Research and Analysis by Region, 2025 Vs 2035 (%)

6. Global Corticosteroids Rheumatoid Arthritis Market Research and Analysis by Region, 2025 vs 2035 (%)

7. Global Conventional Synthetic DMARDs Rheumatoid Arthritis Market Research and Analysis by Region, 2025 vs 2035 (%)

8. Global Biologic DMARDs Rheumatoid Arthritis Market Research and Analysis by Region, 2025 vs 2035 (%)

9. Global Targeted Synthetic DMARDs Rheumatoid Arthritis Market Research and Analysis by Region, 2025 Vs 2035 (%)

10. Global Rheumatoid Arthritis Market Size by Route of Administration, 2025 Vs 2035 (%)

11. Global Oral Rheumatoid Arthritis Market Research and Analysis by Region, 2025 Vs 2035 (%)

12. Global Injectable Rheumatoid Arthritis Market Research and Analysis by Region, 2025 vs 2035 (%)

13. Global Rheumatoid Arthritis Market Size by Region, 2025 vs 2035 (%)

14. United States Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

15. Canada Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

16. UK Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

17. France Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

18. Germany Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

19. Italy Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

20. Spain Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

21. Russia Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

22. India Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

23. China Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

24. Japan Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

25. South Korea Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

26. Australia & New Zealand Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

27. ASEAN Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

28. Rest of Asia-Pacific Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

29. Latin America Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

30. Middle East & Africa Rheumatoid Arthritis Market Size, 2025-2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The rheumatoid arthritis market was valued at $54 billion in 2025 and is projected to reach $90 billion by 2035.
The market is expected to grow at a CAGR of 5.2% during 2026 to 2035.
Biologic DMARDs dominate the market due to their high efficacy in treating moderate-to-severe rheumatoid arthritis.
North America, particularly the United States, leads the market due to advanced healthcare infrastructure and high drug adoption rates.
Key trends include the rise of biologics, increasing adoption of JAK inhibitors, and growing focus on personalized medicine.